1 line
12 KiB
Plaintext
1 line
12 KiB
Plaintext
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T05:14:20Z","timestamp":1679462060051},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Most of the patients with head and neck squamous cell carcinoma (HNSCC) are diagnosed with locally advanced disease. Standards of care for curative-intent treatment of this patient group are either surgery and adjuvant radio(chemo)therapy (aRCT) or definitive chemoradiation. Despite these treatments, especially pathologically intermediate and high-risk HNSCC often recur. The ADRISK trial investigates in locally advanced HNSCC and intermediate and high risk after up-front surgery if the addition of pembrolizumab to aRCT with cisplatin improves event-free sur-vival compared to aRCT alone. ADRISK is a prospective, randomized controlled investiga-tor-initiated (IIT)-phase II multicenter trial within the German Interdisciplinary Study Group of German Cancer Society (IAG-KHT). Patients with primary resectable stage III and IV HNSCC of the oral cavity, oropharynx, hypopharynx and larynx with pathologic high (R1, extracapsular nodal extension) or intermediate risk (R0 &lt;5 mm; N\u22652) after surgery will be eligible. Two hun-dred forty patients will be randomly assigned (1:1) to either standard aRCT with cisplatin (standard arm) or aRCT with cisplatin + pembrolizumab (200 mg iv, in 3-week cycle, max. 12 months) (interventional arm). Endpoints are event-free and overall survival. Recruitment started in August 2018 and is ongoing.<\/jats:p>","DOI":"10.3389\/fonc.2023.1128176","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T06:09:57Z","timestamp":1679378997000},"update-policy":"http:\/\/dx.doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Susanne","family":"Wiegand","sequence":"first","affiliation":[]},{"given":"Gunnar","family":"Wichmann","sequence":"additional","affiliation":[]},{"given":"Jeannette","family":"Vogt","sequence":"additional","affiliation":[]},{"given":"Kathrin","family":"Vogel","sequence":"additional","affiliation":[]},{"given":"Annegret","family":"Franke","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Kuhnt","sequence":"additional","affiliation":[]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[]},{"given":"Anne-Marie","family":"Scheuble","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Hambsch","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[]},{"given":"Franz Georg","family":"Bauernfeind","sequence":"additional","affiliation":[]},{"given":"Holger","family":"Kaftan","sequence":"additional","affiliation":[]},{"given":"Georg","family":"Maschmeyer","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Paland","sequence":"additional","affiliation":[]},{"given":"Marc","family":"M\u00fcnter","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Lewitzki","sequence":"additional","affiliation":[]},{"given":"Nicole","family":"Rotter","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Stromberger","sequence":"additional","affiliation":[]},{"given":"Marcus","family":"Beck","sequence":"additional","affiliation":[]},{"given":"Steffen","family":"Dommerich","sequence":"additional","affiliation":[]},{"given":"Thomas Christoph","family":"Gauler","sequence":"additional","affiliation":[]},{"given":"Gunnar","family":"Hapke","sequence":"additional","affiliation":[]},{"given":"Orlando","family":"Guntinas-Lichius","sequence":"additional","affiliation":[]},{"given":"Ursula","family":"Schr\u00f6der","sequence":"additional","affiliation":[]},{"given":"Martin","family":"G\u00f6rner","sequence":"additional","affiliation":[]},{"given":"Matthias G.","family":"Hautmann","sequence":"additional","affiliation":[]},{"given":"Felix","family":"Steger","sequence":"additional","affiliation":[]},{"given":"B\u00e1lint","family":"Tamaskovics","sequence":"additional","affiliation":[]},{"given":"Anett","family":"Schmiedeknecht","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Dietz","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032646","article-title":"Radiation therapy oncology group 9501\/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","article-title":"Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96\u20133","author":"Fietkau","year":"2006","journal-title":"J Clin Oncol","DOI":"10.1200\/jco.2006.24.18_suppl.5507"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0628","article-title":"Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer","volume":"14","author":"Sheth","year":"2018","journal-title":"Future Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-011-0015-x","article-title":"Der ICRU-report 83: The ICRU report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)","volume":"188","author":"Hodapp","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"B10","volume-title":"Prescribing, recording, and reporting photon-beam therapy","year":"1993"},{"key":"B11","volume-title":"Prescribing, recording, and reporting photon-beam therapy (Supplement to ICRU report 50)","year":"1999"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.10.010","article-title":"Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines","volume":"110","author":"Gr\u00e9goire","year":"2014","journal-title":"Radiother Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.radonc.2015.07.041","article-title":"CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG oncology and TROG consensus guidelines","volume":"117","author":"Brouwer","year":"2015","journal-title":"Radiother Oncol"},{"key":"B14","first-page":"66","article-title":"Clinical trials: a practical approach","volume-title":"Methods of Randomization","author":"Pocock","year":"1993"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.05.008","article-title":"Long-term follow-up of the RTOG 9501\/intergroup phase III trial: Postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck","volume":"84","author":"Cooper","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00106-016-0191-1","article-title":"Curative treatment of head and neck squamous cell carcinoma: Organ preservation strategies in clinical routine in German-speaking countries","volume":"64","author":"Kurzweg","year":"2016","journal-title":"HNO"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc1089","article-title":"Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)","volume":"33","author":"Machiels","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1128176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T06:10:03Z","timestamp":1679379003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1128176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":20,"alternative-id":["10.3389\/fonc.2023.1128176"],"URL":"http:\/\/dx.doi.org\/10.3389\/fonc.2023.1128176","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":["Cancer Research","Oncology"],"published":{"date-parts":[[2023,3,21]]}}} |